Objective—To develop and psychometrically test an owner self-administered questionnaire designed to assess severity and impact of chronic pain in dogs with osteoarthritis.
Sample Population—70 owners of dogs with osteoarthritis and 50 owners of clinically normal dogs.
Procedures—Standard methods for the stepwise development and testing of instruments designed to assess subjective states were used. Items were generated through focus groups and an expert panel. Items were tested for readability and ambiguity, and poorly performing items were removed. The reduced set of items was subjected to factor analysis, reliability testing, and validity testing.
Results—Severity of pain and interference with function were 2 factors identified and named on the basis of the items contained in them. Cronbach's α was 0.93 and 0.89, respectively, suggesting that the items in each factor could be assessed as a group to compute factor scores (ie, severity score and interference score). The test-retest analysis revealed κ values of 0.75 for the severity score and 0.81 for the interference score. Scores correlated moderately well (r = 0.51 and 0.50, respectively) with the overall quality-of-life (QOL) question, such that as severity and interference scores increased, QOL decreased. Clinically normal dogs had significantly lower severity and interference scores than dogs with osteoarthritis.
Conclusions and Clinical Relevance—A psychometrically sound instrument was developed. Responsiveness testing must be conducted to determine whether the questionnaire will be useful in reliably obtaining quantifiable assessments from owners regarding the severity and impact of chronic pain and its treatment on dogs with osteoarthritis.
Procedures—Owners completed the CBPI on day 0. Dogs received carprofen or a placebo on days 1 through 14. Owners completed the CBPI again on day 14. Pain severity and pain interference scores from the CBPI were calculated, and the change from day 0 to day 14 was assessed within each group and between groups.
Results—No significant differences were detected in median scores for pain severity (3.50 and 3.25 on days 0 and 14, respectively) and pain interference (3.92 and 3.25 on days 0 and 14, respectively) in dogs receiving the placebo. Dogs receiving carprofen had significant changes in median scores for pain severity (4.25 to 2.25 on days 0 and 14, respectively) and pain interference (4.33 to 2.67 on days 0 and 14, respectively). There was a significantly greater improvement in pain severity and pain interference scores in dogs treated with carprofen, compared with improvement in scores for dogs receiving the placebo.
Conclusions and Clinical Relevance—The CBPI was able to detect improvements in pain scores in dogs with osteoarthritis treated with an NSAID or a placebo. These results, in combination with previous reliability and validity testing, support the use of the CBPI to obtain quantifiable assessments from owners regarding the severity and impact of chronic pain and treatment for dogs with osteoarthritis.
Objective—To determine whether a single intranasal
dose of modified-live bovine respiratory syncytial
virus (BRSV) vaccine protects calves from BRSV challenge
and characterize cell-mediated immune
response in calves following BRSV challenge.
Animals—13 conventionally reared 4- to 6-week-old
Procedure—Calves received intranasal vaccination
with modified live BRSV vaccine (VC-group calves;
n = 4) or mock vaccine (MC-group calves; 6) 1 month
before BRSV challenge; unvaccinated control-group
calves (n = 3) underwent mock challenge. Serum
virus neutralizing (VN) antibodies were measured on
days –30, -14, 0, and 7 relative to BRSV challenge;
nasal swab specimens were collected for virus isolation
on days 0 to 7. At necropsy examination on day 7,
tissue specimens were collected for measurement of
BRSV-specific interferon gamma (IFN-γ) production.
Tissue distribution of CD3+ T and BLA.36+ B cells
was evaluated by use of immunohistochemistry.
Results—The MC-group calves had significantly higher
rectal temperatures, respiratory rates, and clinical
scores on days 5 to 7 after BRSV challenge than VCgroup
calves. No difference was seen between distributions
of BRSV in lung tissue of VC- and MC-group
calves. Production of BRSV-specific IFN-γ was
increased in tissue specimens from VC-group calves,
compared with MC- and control-group calves. Virusspecific
IFN-γ production was highest in the mediastinal
lymph node of VC-group calves. Increased numbers
of T cells were found in expanded bronchialassociated
lymphoid tissue and airway epithelium of
Conclusions and Clinical Relevance—An intranasal
dose of modified-live BRSV vaccine can protect calves
against virulent BRSV challenge 1 month later. ( Am J Vet Res 2004;65:363–372)
Objective—To characterize cytokine messenger RNA
(mRNA) expression in intranasally vaccinated calves
after bovine respiratory syncytial virus (BRSV) challenge.
Animals—Twelve 8- to 12-week-old calves.
Procedures—Calves received modified-live BRSV vaccine
(vaccinated) or spent tissue culture medium
(mock-vaccinated) intranasally, followed by challenge
30 days later with BRSV, or mock challenge with spent
tissue culture medium (mock-challenge controls).
Interleukin-4 (IL-4) and interferon-γ (IFN-γ) mRNA was
measured in lungs, bronchoalveolar lavage (BAL) fluid
cells, pharyngeal tonsils, and tracheobronchial lymph
nodes, and tumor necrosis factor-α (TNF-α) mRNA was
measured in lungs and BAL fluid cells by reverse transcriptase-competitive
polymerase chain reaction assay.
Results—Resistance to clinical signs of disease was
conferred in vaccinated calves. Expression of TNF-α
mRNA in lungs and BAL fluid cells was higher in
mock-vaccinated calves than control or vaccinated
calves. In the lung, IL-4 mRNA expression was higher
in vaccinated calves than control or mock-vaccinated
calves. In pharyngeal tonsils, expression of mRNA for
IL-4 and IFN-γ was higher in mock-vaccinated calves
than control calves. In tracheobronchial lymph nodes,
IFN-γ mRNA expression was higher in mock-vaccinated
calves than vaccinated calves.
Conclusions and Clinical Relevance—Although vaccinated
calves had decreased clinical signs of disease after
BRSV challenge, compared with mock-vaccinated calves,
this difference was not related to a T helper type 1 bias,
as determined by increased expression of interferon-γ
mRNA relative to interleukin-4 mRNA in lungs, BAL fluid
cells, or tracheobronchial lymph nodes of vaccinated
calves. Pulmonary inflammation was decreased in vaccinated
calves as determined by decreased expression of
TNF-α mRNA. (Am J Vet Res 2004;65:725–733)
Objective—To estimate spatial risks associated with
mare reproductive loss syndrome (MRLS) during
2001 among horses in a specific study population and
partition the herd effects into those attributable to
herd location and those that were spatially random
and likely attributable to herd management.
Animals—Pregnant broodmares from 62 farms in 7
counties in central Kentucky.
Procedure—Veterinarians provided the 2001 abortion
incidence proportions for each farm included in the
study. Farms were georeferenced and data were analyzed
by use of a fully Bayesian risk-mapping technique.
Results—Large farm-to-farm variation in MRLS incidence
proportions was identified. The farm-to-farm
variation was largely attributed to spatial location
rather than to spatially random herd effects
Conclusions and Clinical Relevance—Results indicate
that there are considerable data to support an
ecologic cause and potential ecologic risk factors for
MRLS. Veterinary practitioners with more detailed
knowledge of the ecology in the 7 counties in
Kentucky that were investigated may provide additional
data that would assist in the deduction of the
causal factor of MRLS via informal geographic information
systems analyses and suggest factors for
inclusion in further investigations. (Am J Vet Res 2005;66:17–20)
To determine whether muscle-sparing laryngoplasty results in fewer changes in swallowing function compared to standard surgical treatment for laryngeal paralysis.
12 clinically normal sexually intact male Beagles.
Group A dogs (n = 4) had a standard approach to the larynx, with left arytenoid cartilage lateralization. Group B dogs (n = 4) had a muscle-sparing laryngoplasty performed with the thyropharyngeus muscle fibers bluntly separated, and the cricoarytenoideus dorsalis muscle spared. Pre- and 24-hour postoperative fluoroscopic swallowing studies were performed and graded. Larynges were harvested after humane euthanasia, and glottic area was measured. Group C dogs (n = 4) acted as controls, with surgical dissection ending lateral to the thyropharyngeus muscle, arytenoid lateralization not performed, and the dogs not euthanized. The study was performed between October 15, 2011 and May 15, 2021.
Changes in pharyngeal and upper esophageal sphincter function were not detected in any group. There was no difference in glottic area between treatment groups. Aspiration of liquid was not a consistent finding. Two dogs in each treatment group developed moderate to severe cervical esophageal paresis. This did not occur in control dogs.
We found no evidence to support our hypothesis that muscle-sparing laryngoplasty results in less severe changes in swallowing function compared to a standard technique. The cervical esophageal paresis identified in both treatment groups could increase the risk of postoperative aspiration pneumonia in dogs treated for laryngeal paralysis via a lateral approach to the larynx. Further study to determine the frequency, cause, and duration of esophageal dysfunction is warranted.
Procedures—The equine myogenic differentiation 1 (eqMyoD) genomic sequence was obtained by use of equine bacterial artificial chromosome screening and PCR sequencing. Total mRNA was extracted from foal skeletal muscle, and eqMyoD cDNA was cloned into a plasmid vector with an internal ribosomal entry site to express bicistronic eqMyoD or enhanced green fluorescent protein (EGFP). Transient expression was confirmed by immunocytochemical analysis and western immunoblots in equine fibroblasts and fibroblasts from National Institutes of Health Swiss mouse embryos, prior to generation of a lentiviral vector containing the same coding sequences. Transformation of equine skin–derived cells into skeletal myotubes was examined by use of immunohistochemical analysis, western immunoblotting, and periodic acid–Schiff staining.
Results—eqMyoD mRNA consists of 960 bp and shares high homology with myogenic differentiation 1 from other mammals. Transfection confirmed the expression of a 53-kd protein with mainly nuclear localization. Lentiviral transduction was efficient, with approximately 80% of EGFP-positive cells transformed into multinucleated myotubes during 15 days, as determined by expression of the muscle-specific proteins desmin, troponin-T, and sarcomeric myosin and by cytoplasmic storage of glycogen.
Conclusions and Clinical Relevance—Equine primary fibroblasts were transformed by lentiviral transduction of eqMyoD into fusion-competent myoblasts. This may offer a preferable alternative to primary myoblast cultures for the investigation of cellular defects associated with muscle diseases of horses, such as recurrent exertional rhabdomyolysis and polysaccharide storage myopathy.
Objective—To determine the items (question topics) for a subjective instrument to assess degenerative joint disease (DJD)–associated chronic pain in cats and determine the instrument design most appropriate for use by cat owners.
Animals—100 randomly selected client-owned cats from 6 months to 20 years old.
Procedures—Cats were evaluated to determine degree of radiographic DJD and signs of pain throughout the skeletal system. Two groups were identified: high DJD pain and low DJD pain. Owner-answered questions about activity and signs of pain were compared between the 2 groups to define items relating to chronic DJD pain. Interviews with 45 cat owners were performed to generate items. Fifty-three cat owners who had not been involved in any other part of the study, 19 veterinarians, and 2 statisticians assessed 6 preliminary instrument designs.
Results—22 cats were selected for each group; 19 important items were identified, resulting in 12 potential items for the instrument; and 3 additional items were identified from owner interviews. Owners and veterinarians selected a 5-point descriptive instrument design over 11-point or visual analogue scale formats.
Conclusions and Clinical Relevance—Behaviors relating to activity were substantially different between healthy cats and cats with signs of DJD-associated pain. Fifteen items were identified as being potentially useful, and the preferred instrument design was identified. This information could be used to construct an owner-based questionnaire to assess feline DJD-associated pain. Once validated, such a questionnaire would assist in evaluating potential analgesic treatments for these patients.
Objective—To determine the incidence of adverse events within 24 hours after contrast-enhanced ultrasonography (CEUS) in dogs and cats and compare the risk of death within 24 hours after imaging for animals that underwent ultrasonography with and without injection of a contrast agent.
Design—Retrospective case-control study.
Animals—750 animals (411 case dogs, 238 control dogs, 77 case cats, and 24 control cats).
Procedures—At 11 institutions, medical records were reviewed of dogs and cats that had CEUS performed (cases) as were medical records of dogs and cats with clinical signs similar to those of case animals that had ultrasonography performed without injection of a contrast agent (controls). Information regarding signalment; preexisting disease; type, dose, and administration route of contrast agent used; immediate (within 1 hour after CEUS) and delayed (> 1 and ≤ 24 hours after CEUS) adverse events; and occurrence and cause of death (when available) was extracted from each medical record. Risk of death within 24 hours after ultrasonography was compared between case and control animals.
Results—Of the 411 case dogs, 3 had immediate adverse events (vomiting or syncope) and 1 had a delayed adverse event (vomiting). No adverse events were recorded for case cats. Twenty-three of 357 (6.4%) clinically ill case animals and 14 of 262 (5.3%) clinically ill control animals died within 24 hours after ultrasonography; risk of death did not differ between cases and controls.
Conclusions and Clinical Relevance—Results indicated that CEUS was safe in dogs and cats.